» Articles » PMID: 29963872

Limited Modulation of the Abuse-related Behavioral Effects of D-methamphetamine by Disulfiram

Overview
Specialty Pharmacology
Date 2018 Jul 3
PMID 29963872
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Disulfiram (Antabuse), an acetaldehyde dehydrogenase and dopamine-beta hydroxylase inhibitor, has shown promise in preclinical and clinical studies as a pharmacotherapy for cocaine addiction. However, the extent to which disulfiram may alter the abuse-related behavioral effects of related psychostimulants, such as methamphetamine, is unknown. Here, the therapeutic potential of disulfiram was evaluated by examining its impact on the reinforcing and discriminative stimulus effects of d-methamphetamine in adult rhesus monkeys (N = 4 per group). In subjects trained to respond for injections of methamphetamine or food delivery, i.v. methamphetamine (.001-.032 mg/kg) maintained dose-related and stable levels of self-administration in all subjects. Pretreatment with disulfiram (5.6 mg/kg) produced a significant downward shift in the d-methamphetamine dose-response function; surprisingly, lower and higher pretreatment doses (3.0 mg/kg; 10 mg/kg) were ineffective. Also, disulfiram (3-10 mg/kg) did not significantly alter food-maintained responding or, in subjects trained to discriminate the effects of cocaine from vehicle, the ability of d-methamphetamine (.032-.32 mg/kg) to substitute for cocaine. Taken together, the present data reveal dose-dependent effects of disulfiram in modifying some of the abuse-related effects of d-methamphetamine and provides support for future investigations examining the capacity of disulfiram as a treatment for d-methamphetamine abuse. (PsycINFO Database Record (c) 2018 APA, all rights reserved).

Citing Articles

Methamphetamine-mediated astrocytic pyroptosis and neuroinflammation involves miR-152-NLRP6 inflammasome signaling axis.

Oladapo A, Kannan M, Deshetty U, Singh S, Buch S, Periyasamy P Redox Biol. 2025; 80:103517.

PMID: 39879739 PMC: 11810843. DOI: 10.1016/j.redox.2025.103517.


Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats.

Frankowska M, Surowka P, Suder A, Pieniazek R, Puklo R, Jastrzebska J Pharmacol Rep. 2021; 73(6):1694-1711.

PMID: 34236605 PMC: 8599263. DOI: 10.1007/s43440-021-00307-2.

References
1.
Cooper D, Kimmel H, Manvich D, Schmidt K, Weinshenker D, Howell L . Effects of pharmacologic dopamine β-hydroxylase inhibition on cocaine-induced reinstatement and dopamine neurochemistry in squirrel monkeys. J Pharmacol Exp Ther. 2014; 350(1):144-52. PMC: 4056266. DOI: 10.1124/jpet.113.212357. View

2.
Kohut S, Fivel P, Mello N . Differential effects of acute and chronic treatment with the α2-adrenergic agonist, lofexidine, on cocaine self-administration in rhesus monkeys. Drug Alcohol Depend. 2013; 133(2):593-9. PMC: 3818349. DOI: 10.1016/j.drugalcdep.2013.07.032. View

3.
Carroll K, Nich C, Ball S, MCCANCE E, Frankforter T, Rounsaville B . One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction. 2000; 95(9):1335-49. DOI: 10.1046/j.1360-0443.2000.95913355.x. View

4.
Kosten T, Jatlow P . Chronic disulfiram treatment effects on intranasal cocaine administration: initial results. Biol Psychiatry. 1998; 43(7):540-3. DOI: 10.1016/S0006-3223(97)00506-4. View

5.
Gonzales R, Mooney L, Rawson R . The methamphetamine problem in the United States. Annu Rev Public Health. 2010; 31:385-98. PMC: 4440680. DOI: 10.1146/annurev.publhealth.012809.103600. View